Table 2.
Provider view of patient difficulties and their role in shared decision-making (SDM) process in gout
| Often | Sometimes | Rarely | Never | Don’t know | |
|---|---|---|---|---|---|
| Q1. How common is it for your patients to have difficulty starting urate-lowering therapy vs. doing nothing…. | |||||
| a. Unsure about the best choice for them? | 11 (14%) | 41 (51%) | 25 (31%) | 2 (2%) | 1 (1%) |
| b. Uninformed about both benefits and risks? | 28 (36%) | 23 (29%) | 22 (28%) | 5 (6%) | 0 (0%) |
| c. Unclear about the personal importance of the benefits and risks? | 32 (58%) | 26 (33%) | 16 (20%) | 4 (5%) | 1 (1%) |
| d. Unsupported in decision-making? | 8 (10%) | 29 (37%) | 25 (32%) | 11 (14%) | 5 (6%) |
| Q2. How common is it for your patients to have difficulty choosing between non-steroidal anti-inflammatory drugs (NSAIDs), steroids or colchicine for the treatment of acute flares… | |||||
| a. Unsure about the best choice for them? | 20 (26%) | 35 (45%) | 23 (18%) | 9 (6%) | 4 (5%) |
| b. Uninformed about both benefits and risks? | 22 (28%) | 28 (36%) | 18 (23%) | 7 (9%) | 3 (4%) |
| c. Unclear about the personal importance of the benefits and risks? | 22 (28%) | 33 (42%) | 12 (15%) | 7 (9%) | 4 (5%) |
| d. Unsupported in decision-making? | 10 (13%) | 27 (35%) | 19 (25%) | 12 (16%) | 8 (10%) |
| Q3. How common is it for your patients to have difficulty choosing between NSAIDs, steroids, or colchicine for prophylaxis when starting ULTs… | |||||
| a. Unsure about the best choice for them? | 22 (28%) | 32 (42%) | 13 (17%) | 5 (7%) | 4 (5%) |
| b. Uninformed about both benefits and risks? | 25 (33%) | 22 (29%) | 16 (21%) | 9 (12%) | 4 (5%) |
| c. Unclear about the personal importance of the benefits and risks? | 26 (35%) | 23 (32%) | 14 (19%) | 7 (9%) | 4 (5%) |
| d. Unsupported in decision-making? | 11 (14%) | 29 (38%) | 17 (22%) | 12 (16%) | 8 (10%) |
| Q4. How common is it for your patients to have difficulty choosing between allopurinol vs. febuxostat as a first urate-lowering therapy (ULT)…. | |||||
| a. Unsure about the best choice for them? | 15 (20%) | 12 (16%) | 24 (32%) | 12 (16%) | 13 (16%) |
| b. Uninformed about both benefits and risks? | 17 (23%) | 16 (21%) | 17 (23%) | 12 (16%) | 13 (17%) |
| c. Unclear about the personal importance of the benefits and risks? | 19 (25%) | 21 (28%) | 11 (15%) | 14 (13%) | 14 (19%) |
| d. Unsupported in decision-making? | 9 (12%) | 18 (24%) | 17 (23%) | 17 (23%) | 14 (19%) |
| Q5. How common is it for your patients to have difficulty choosing whether to take daily ULT and continue taking it long-term vs. intermittently….. | |||||
| a. Unsure about the best choice for them? | 18 (24%) | 16 (21%) | 22 (29%) | 13 (17%) | 8 (10%) |
| b. Uninformed about both benefits and risks? | 19 (25%) | 19 (25%) | 19 (25%) | 11 (15%) | 8 (10%) |
| c. Unclear about the personal importance of the benefits and risks? | 20 (26%) | 20 (26%) | 18 (24%) | 11 (14%) | 8 (10%) |
| d. Unsupported in decision-making? | 12 (16%) | 18 (24%) | 20 (26%) | 15 (20%) | 11 (14%) |
Missing data: Q1, n=10; Q4, n=15; Q5, n=13; Q2, n=12; Q3, n=13